|
04.01.2016 08:30:00
|
Poxel Announces its 2016 Financial Calendar
Poxel SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today announces its schedule for the publication of financial information for 2016.
| Event | Date * | |||||
| 2015 Full-Year Sales | January 28, 2016 – After market closes | |||||
| 2015 Full-Year Financial Statement | March 31, 2016 – After market closes | |||||
| 2016 Q1 Sales | May 5, 2016 – Before market opens | |||||
| 2016 Q2 Sales | July 15, 2016 – Before market opens | |||||
| 2016 June 30th, Financial Statement | September 12, 2016 – Before market opens | |||||
| 2016 Q3 Sales | October 21, 2016 – Before market opens | |||||
| 2016 Full-Year Sales | January 27, 2017 – Before market opens | |||||
|
|
||||||
About Poxel
Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed Phase 2 development in the US and EU and has started Phase 2b development in Japanese patients. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)
View source version on businesswire.com: http://www.businesswire.com/news/home/20160103005058/en/
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Poxel SAmehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu Poxel SAmehr Analysen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.